Related Experiment Videos

Mycobacterium kansasii infections in Western Australia (1962-1987)

S C Pang1

  • 1Chest Service, Health Department of Western Australia, Perth.

Insights

Mycobacterium kansasii infections are rare but treatable, primarily affecting the lungs in middle-aged Caucasian males in Western Australia. Drug regimens, especially rifampicin/ethambutol, show high success rates within 12 months.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Epidemiology

Background:

  • Mycobacterium kansasii is an atypical mycobacterium that can cause disease in humans.
  • Understanding the epidemiology and clinical presentation of M. kansasii infections is crucial for effective management.

Purpose of the Study:

  • To review the records of patients with M. kansasii isolations in Western Australia over 26 years.
  • To describe the demography, clinical manifestations, and treatment outcomes of M. kansasii infections.

Main Methods:

  • Retrospective review of patient records with M. kansasii isolations.
  • Analysis of demographic data, infection sites, and treatment responses.

Main Results:

  • 40 episodes of M. kansasii disease were identified in 39 patients, predominantly pulmonary (90%).
  • The average incidence was 0.14 per 100,000 person-years, with higher rates in the Geraldton Mid-west region.
  • Pulmonary cases primarily affected Caucasian males (mean age 53), often miners and smokers. Treatment with rifampicin/ethambutol was highly successful within 12 months.

Conclusions:

  • M. kansasii infections in Western Australia are infrequent, with pulmonary disease being the most common manifestation.
  • Risk factors for pulmonary M. kansasii include male gender, Caucasian ethnicity, mining occupation, and smoking.
  • Standard drug treatment regimens, particularly rifampicin/ethambutol, are effective for M. kansasii infections.

Related Concept Videos